Together, these results validate our pan-cancer observations that CpG hypermutation has the highest prevalence in colorectal cancer and glioma, is genetically linked to MSH2/MSH6-deficiency, and highlights a potential predictive relevance for ICI therapies. This evidence concerns the gene MSH6 and glioma.